Angiotech Pharmaceuticals

ANP-T

0.00
0.00 (0.00%)
This company is not ACTIVE.

Analysis and Opinions about ANP-T

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
February 1, 2010
What hurts them was they levered up for an acquisition using debt at the wrong time and have never been able to get out from under that cloud of debt and he doesn't think they will.
Show full opinionHide full opinion
What hurts them was they levered up for an acquisition using debt at the wrong time and have never been able to get out from under that cloud of debt and he doesn't think they will.
BUY WEAKNESS
BUY WEAKNESS
June 22, 2009
(Market Call Minute.) A lot of biotech stocks have done well. Would buy on a pullback.
Show full opinionHide full opinion
(Market Call Minute.) A lot of biotech stocks have done well. Would buy on a pullback.
DON'T BUY
DON'T BUY
June 12, 2009
Had 2 approvals, May 27 and June 8. This is on his Watch list but was far more interesting before May 27 so it now holds no interest for him. Might be okay for momentum players.
Show full opinionHide full opinion
Had 2 approvals, May 27 and June 8. This is on his Watch list but was far more interesting before May 27 so it now holds no interest for him. Might be okay for momentum players.
COMMENT
COMMENT
December 11, 2007
The stock has been hurt, but it is more of an issue because of stents. Sales projections are falling off. At this stage, you are probably facing tax loss selling for the rest of the month and then get a January bounce if the company has a decent outlook going forward. Competition has increased in this area.
Show full opinionHide full opinion
The stock has been hurt, but it is more of an issue because of stents. Sales projections are falling off. At this stage, you are probably facing tax loss selling for the rest of the month and then get a January bounce if the company has a decent outlook going forward. Competition has increased in this area.
HOLD
HOLD
July 5, 2007
Have had serious problems with their stents. The whole area is having issues. Excellent management. They have big pipeline and the technology is still excellent.
Show full opinionHide full opinion
Have had serious problems with their stents. The whole area is having issues. Excellent management. They have big pipeline and the technology is still excellent.
SELL
SELL
June 1, 2007
The whole market is going up, and this one is going down. Let someone else own it.
Show full opinionHide full opinion
The whole market is going up, and this one is going down. Let someone else own it.
SELL
SELL
May 1, 2007
A one trick pony with its coated stent. There is lots of controversy on drug coated stents.
Show full opinionHide full opinion
A one trick pony with its coated stent. There is lots of controversy on drug coated stents.
DON'T BUY
DON'T BUY
April 19, 2007
They're very focused on one part of the business, which is stents. There is a lot of competition in this sector. Revenue projections have been dropping.
Show full opinionHide full opinion
They're very focused on one part of the business, which is stents. There is a lot of competition in this sector. Revenue projections have been dropping.
COMMENT
COMMENT
April 17, 2007
Makes drug alluding stents. Its penetration rate in the US was 75% but has dropped to 65%. Will be launching in Japan in the fall. Have a lot of debt on the balance sheet and are in the process of selling assets.
Show full opinionHide full opinion
Makes drug alluding stents. Its penetration rate in the US was 75% but has dropped to 65%. Will be launching in Japan in the fall. Have a lot of debt on the balance sheet and are in the process of selling assets.
BUY
BUY
April 2, 2007
The worst news is already in the stock. At these levels, it's a Buy. Have product pipeline starting to develop. Looking at drug eluding stents in the Japanese market.
Show full opinionHide full opinion
The worst news is already in the stock. At these levels, it's a Buy. Have product pipeline starting to develop. Looking at drug eluding stents in the Japanese market.
DON'T BUY
DON'T BUY
March 28, 2007
A “ one trick pony”. There are now lots of questions to the effectiveness of drug-coated stents.
Show full opinionHide full opinion
A “ one trick pony”. There are now lots of questions to the effectiveness of drug-coated stents.
DON'T BUY
DON'T BUY
March 12, 2007
Not time to buy this one yet. They have the stent problem and the adoption problem. Lowering their earnings forecasts. Potential recovery, but wait for the recovery.
Show full opinionHide full opinion
Not time to buy this one yet. They have the stent problem and the adoption problem. Lowering their earnings forecasts. Potential recovery, but wait for the recovery.
DON'T BUY
DON'T BUY
March 12, 2007
Had a long-term problem with stents. Made a series of acquisitions which all look very interesting. Not sure what the effect of this will be. A raving buy at this price, but does not like buying a stock on the way down.
Show full opinionHide full opinion
Had a long-term problem with stents. Made a series of acquisitions which all look very interesting. Not sure what the effect of this will be. A raving buy at this price, but does not like buying a stock on the way down.
DON'T BUY
DON'T BUY
March 9, 2007
If it breaks $7.35, it is going to go lower. His model price is hugely coming down. In September it was $16 and now it is $10.73, which is a positive differential, but earnings are dropping.
Show full opinionHide full opinion
If it breaks $7.35, it is going to go lower. His model price is hugely coming down. In September it was $16 and now it is $10.73, which is a positive differential, but earnings are dropping.
DON'T BUY
DON'T BUY
February 13, 2007
Guidance for this year was quite poor. Their stent business is not going to be as robust. Company needs to diversify their asset base and have been slow to do that.
Show full opinionHide full opinion
Guidance for this year was quite poor. Their stent business is not going to be as robust. Company needs to diversify their asset base and have been slow to do that.
Showing 1 to 15 of 140 entries

Angiotech Pharmaceuticals(ANP-T) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Angiotech Pharmaceuticals is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Angiotech Pharmaceuticals(ANP-T) Frequently Asked Questions

What is Angiotech Pharmaceuticals stock symbol?

Angiotech Pharmaceuticals is a OTC stock, trading under the symbol ANP-T on the (). It is usually referred to as or ANP-T

Is Angiotech Pharmaceuticals a buy or a sell?

In the last year, there was no coverage of Angiotech Pharmaceuticals published on Stockchase.

Is Angiotech Pharmaceuticals a good investment or a top pick?

Angiotech Pharmaceuticals was recommended as a Top Pick by John Zechner on 2010-02-01. Read the latest stock experts ratings for Angiotech Pharmaceuticals.

Why is Angiotech Pharmaceuticals stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Angiotech Pharmaceuticals worth watching?

In the last year, there was no coverage of Angiotech Pharmaceuticals published on Stockchase.

What is Angiotech Pharmaceuticals stock price?

On , Angiotech Pharmaceuticals (ANP-T) stock closed at a price of $.